P190-type bcr/abl expressed in myeloid colonies in a patient with Ph1-positive acute lymphoblastic leukemia.

abstract：:Although allogeneic bone marrow transplantation has been shown to be a highly effective treatment for acute and chronic leukemia, leukemic relapse remains a significant problem. Leukemic relapse occurs in recipient cells in the majority of cases, but the paucity of donor cell leukemias may reflect the sensitivity of t...

journal_title：Leukemia

authors： Mc Cann SR,Lawler M,Gardiner N,O'Riordan J,Humphries P,De Arce M

更新日期：1994-04-01 00:00:00

abstract：:Clonal chromosome abnormalities were detected in bone marrow cells of 20 patients with Fanconi anemia investigated at various stages of the disease. Two presented with acute leukemia, six with myelodysplastic syndrome, and 12 had minor or no morphological abnormalities of hematopoietic cells. Abnormalities of chromoso...

journal_title：Leukemia

authors： Maarek O,Jonveaux P,Le Coniat M,Derré J,Berger R

更新日期：1996-11-01 00:00:00

abstract：:The clinical and cell growth characteristics of 11 children with monosomy 7 presenting as preleukemia (eight cases) or acute nonlymphoblastic leukemia (three cases) were studied. Anemia was common to all patients, with nine showing leukocytosis, seven thrombocytopenia, and one thrombocytosis. There was a striking pred...

journal_title：Leukemia

authors： Weiss K,Stass S,Williams D,Kalwinsky D,Dahl GV,Wang W,Johnson FL,Murphy SB,Dow LW

更新日期：1987-02-01 00:00:00

abstract：:The acquired kinase mutation JAK2V617F plays a central role in myeloproliferative neoplasms (MPNs). However, the mechanisms responsible for the malignant hematopoietic stem/progenitor cell (HSPC) expansion seen in patients with MPNs are not fully understood, limiting the effectiveness of current treatment. Endothelial...

journal_title：Leukemia

authors： Zhan H,Lin CHS,Segal Y,Kaushansky K

更新日期：2018-02-01 00:00:00

abstract：:Imatinib is a highly effective therapy for chronic phase-chronic myeloid leukaemia (CP-CML) patients; however, responses to frontline imatinib are variable. The human organic cation transporter 1 (OCT1; SLC22A1) has been reported to be the main influx transporter involved in imatinib uptake into CML cells. Furthermore...

journal_title：Leukemia

authors： Watkins DB,Hughes TP,White DL

更新日期：2015-10-01 00:00:00

abstract：:Chronic lymphocytic leukemia cells (CLL) migrate between the blood and lymphoid tissues in response to chemokines. Such migration requires structured cytoskeletal-actin polymerization, which may involve the protein cortactin. We discovered that treatment of CLL cells with Wnt5a causes Receptor tyosin kinase-like orpha...

journal_title：Leukemia

authors： Hasan MK,Rassenti L,Widhopf GF 2nd,Yu J,Kipps TJ

更新日期：2019-03-01 00:00:00

abstract：:Fourteen patients (M/F, 6/8; age, 48/23-64 yrs) with relapsing or primary resistant intermediate-high grade non-Hodgkin lymphomas were treated with ARA-C (2 g/m2 x 4 on days 1 and 2), DDP (100 mg/m2 96 hr infusion) and VP-16 (150 mg/m2 on days 1, 2 and 3). GM-CSF or placebo was administered from the 5th day until neut...

journal_title：Leukemia

authors： Liberati AM,Cinieri S,Schippa M,Di Clemente F,Filippo S,Grignani F

更新日期：1991-01-01 00:00:00

abstract：:There is a clear association between the Epstein-Barr virus (EBV) and Hodgkin's disease (HD). EBV is not, however, detectable within the affected tissues of all cases. The proportion of positive cases varies from 15-79% depending on the assay used to detect EBV. The techniques utilised vary not only in sensitivity but...

journal_title：Leukemia

authors： Armstrong AA,Weiss LM,Gallagher A,Jones DB,Krajewski AS,Angus B,Brown G,Jack AS,Wilkins BS,Onions DE

更新日期：1992-09-01 00:00:00

abstract：:Deletions from the derivative chromosome 9, der(9), of the translocation, t(9;22)(q34;q11), at the site of the ABL/BCR fusion gene, have been demonstrated by fluorescence in situ hybridisation (FISH), in both Philadelphia chromosome (Ph)-positive chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL)....

journal_title：Leukemia

authors： Robinson HM,Martineau M,Harris RL,Barber KE,Jalali GR,Moorman AV,Strefford JC,Broadfield ZJ,Cheung KL,Harrison CJ

更新日期：2005-04-01 00:00:00

abstract：:Hematopoietic stem cell transplantation is becoming an increasingly important approach to treatment of different malignant and non-malignant disorders. There is thus growing demand for diagnostic assays permitting the surveillance of donor/recipient chimerism posttransplant. Current techniques are heterogeneous, rende...

journal_title：Leukemia

authors： Lion T,Watzinger F,Preuner S,Kreyenberg H,Tilanus M,de Weger R,van Loon J,de Vries L,Cavé H,Acquaviva C,Lawler M,Crampe M,Serra A,Saglio B,Colnaghi F,Biondi A,van Dongen JJ,van der Burg M,Gonzalez M,Alcoceba M,Bar

更新日期：2012-08-01 00:00:00

abstract：:Translocation (15;17)(q22;q12-q21) is a chromosome aberration specifically found in acute promyelocytic leukemia (APL), that generates a chimeric gene between the promyelocytic leukemia (PML) gene on chromosome 15 and the retinoic acid receptor alpha (RARA) gene, on chromosome 17. In the course of molecular investigat...

journal_title：Leukemia

authors： Geng JP,Tong JH,Dong S,Wang ZY,Chen SJ,Chen Z,Zelent A,Berger R,Larsen CJ

更新日期：1993-01-01 00:00:00

abstract：:Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare disease that currently lacks genomic and genetic biomarkers to assist in its clinical management. We performed whole-exome sequencing (WES) of three BPDCN cases. Based on these data, we designed a resequencing approach to identify mutations in 38 sele...

journal_title：Leukemia

authors： Menezes J,Acquadro F,Wiseman M,Gómez-López G,Salgado RN,Talavera-Casañas JG,Buño I,Cervera JV,Montes-Moreno S,Hernández-Rivas JM,Ayala R,Calasanz MJ,Larrayoz MJ,Brichs LF,Gonzalez-Vicent M,Pisano DG,Piris MA,Álvarez S,

更新日期：2014-04-01 00:00:00

abstract：:The EU-supported EuroFlow Consortium aimed at innovation and standardization of immunophenotyping for diagnosis and classification of hematological malignancies by introducing 8-color flow cytometry with fully standardized laboratory procedures and antibody panels in order to achieve maximally comparable results among...

journal_title：Leukemia

authors： Kalina T,Flores-Montero J,van der Velden VH,Martin-Ayuso M,Böttcher S,Ritgen M,Almeida J,Lhermitte L,Asnafi V,Mendonça A,de Tute R,Cullen M,Sedek L,Vidriales MB,Pérez JJ,te Marvelde JG,Mejstrikova E,Hrusak O,Szczepańs

更新日期：2012-09-01 00:00:00

abstract：:Depending on disease stage follicular lymphoma (FL) lack the t(14;18) in ~15-~50% of cases. Nevertheless, most of these cases express BCL2. To elucidate mechanisms triggering BCL2 expression and promoting pathogenesis in t(14;18)-negative FL, exonic single-nucleotide variant (SNV) profiles of 28 t(14;18)-positive and ...

journal_title：Leukemia

authors： Zamò A,Pischimarov J,Schlesner M,Rosenstiel P,Bomben R,Horn H,Grieb T,Nedeva T,López C,Haake A,Richter J,Trümper L,Lawerenz C,Klapper W,Möller P,Hummel M,Lenze D,Szczepanowski M,Flossbach L,Schreder M,Gattei V,O

更新日期：2018-03-01 00:00:00

abstract：:The p53 tumor suppressor gene is frequently mutated within its evolutionarily conserved regions in a number of human cancers. Previous reports demonstrated mutations of this gene in both Burkitt's lymphoma and B cell chronic lymphocytic leukemia. However, dissimilar results were obtained in non-Hodgkin's lymphoma (NHL...

journal_title：Leukemia

authors： Li CC,O'Connell CD,Beckwith M,Longo DL

更新日期：1995-04-01 00:00:00

abstract：:CD31/PECAM-1 (platelet endothelial cell adhesion molecule-1) is a 130 kDa integral membrane protein of the immunoglobulin gene superfamily with the distinctive feature of being expressed on several cell types associated with the vascular compartment. In the present study we report a novel, unique CD31 mAb termed IP28A...

journal_title：Leukemia

authors： El-Marsafy S,Carosella ED,Agrawal SG,Gluckman E,Mansur IG,Elhabazi A,Boumsell L,Bensussan A

更新日期：1996-08-01 00:00:00

abstract：:The immune response to leukemia is poorly understood. We postulated that nonmalignant T lymphocytes remaining within bone marrow from children with newly diagnosed ALL could be involved in this immune response. T lymphocytes which expressed gamma delta TCR comprised less than 1% of ALL marrow cells. A preferential out...

journal_title：Leukemia

authors： Duval M,Yotnda P,Bensussan A,Oudhiri N,Guidal C,Rohrlich P,Boumsell L,Grandchamp B,Vilmer E

更新日期：1995-05-01 00:00:00

abstract：:The T-lineage phenotype in children with acute lymphoblastic leukaemia (ALL) is associated with in vitro drug resistance and a higher relapse-risk compared to a precursor B phenotype. Our study was aimed to investigate whether mutations in the ATM gene occur in childhood T-lineage acute lymphoblastic leukaemia (T-ALL)...

journal_title：Leukemia

authors： Meier M,den Boer ML,Hall AG,Irving JA,Passier M,Minto L,van Wering ER,Janka-Schaub GE,Pieters R

更新日期：2005-11-01 00:00:00

abstract：:To evaluate the clinical usefulness of IL-2 in myelodysplastic syndromes (MDS) the in vitro effects of interleukin-2 (IL-2) on blast cell proliferation, clonogenic activity, cytokine release and cell mediated cytotoxicity were examined in 49 MDS patients. Morphological analyses of bone marrow (BM) cytospin preparation...

journal_title：Leukemia

authors： Cortelezzi A,Sarina B,Cattaneo C,Pomati M,Silvestris I,Soligo D,Calori R,Di Stefano M,Hu C,Monza M,Radelli L,Maiolo AT

更新日期：1996-07-01 00:00:00

abstract：:To determine the clinical significance of minimal residual disease (MRD) in patients with prognostically relevant subtypes of childhood acute lymphoblastic leukemia (ALL), we analyzed data from 488 patients treated in St Jude Total Therapy Study XV with treatment intensity based mainly on MRD levels measured during re...

journal_title：Leukemia

authors： Pui CH,Pei D,Raimondi SC,Coustan-Smith E,Jeha S,Cheng C,Bowman WP,Sandlund JT,Ribeiro RC,Rubnitz JE,Inaba H,Gruber TA,Leung WH,Yang JJ,Downing JR,Evans WE,Relling MV,Campana D

更新日期：2017-02-01 00:00:00

abstract：:T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological cancer characterized by skewed epigenetic patterns, raising the possibility of therapeutically targeting epigenetic factors in this disease. Here we report that among different cancer types, epigenetic factor TET1 is highly expressed in T-ALL a...

journal_title：Leukemia

authors： Bamezai S,Demir D,Pulikkottil AJ,Ciccarone F,Fischbein E,Sinha A,Borga C,Te Kronnie G,Meyer LH,Mohr F,Götze M,Caiafa P,Debatin KM,Döhner K,Döhner H,González-Menéndez I,Quintanilla-Fend L,Herold T,Jeremias I,Feuring-

更新日期：2020-05-15 00:00:00

abstract：:Signal transducer and activator of transcription (Stat)3 is constitutively activated in cutaneous T-cell lymphoma (CTCL), where it protects tumour cells against apoptosis. The constitutive activation of Stat3 leads to a constitutive expression of suppressor of cytokine signalling (SOCS)-3. In healthy cells, SOCS-3 is ...

journal_title：Leukemia

authors： Brender C,Lovato P,Sommer VH,Woetmann A,Mathiesen AM,Geisler C,Wasik M,Ødum N

更新日期：2005-02-01 00:00:00

abstract：:The BCL-2 inhibitor venetoclax has only limited activity in DLBCL despite frequent BCL-2 overexpression. Since constitutive activation of the B cell receptor (BCR) pathway has been reported in both ABC and GCB DLBCL, we investigated whether targeting SYK or BTK will increase sensitivity of DLBCL cells to venetoclax. W...

journal_title：Leukemia

authors： Sasi BK,Martines C,Xerxa E,Porro F,Kalkan H,Fazio R,Turkalj S,Bojnik E,Pyrzynska B,Stachura J,Zerrouqi A,Bobrowicz M,Winiarska M,Priebe V,Bertoni F,Mansouri L,Rosenquist R,Efremov DG

更新日期：2019-10-01 00:00:00

abstract：:Chimeric antigen receptor (CAR) T cell therapies lead to high clinical response rates in B cell malignancies, and are under investigation for treatment of solid tumors. While high systemic interleukin- (IL-) 6 levels are associated with clinical cytokine release syndrome (CRS), the role of IL-6 trans-signaling within ...

journal_title：Leukemia

authors： Jiang Z,Liao R,Lv J,Li S,Zheng D,Qin L,Wu D,Chen S,Long Y,Wu Q,Wang S,Lin S,Huang X,Tang Z,Shi P,Zhou H,Liu Q,Zhao R,Li Y,Jie Y,Wei W,Lai P,Du X,Cui S,Weinkove R,Liu P,Pei D,Yao Y,Li P

更新日期：2020-11-09 00:00:00

abstract：:Imatinib is usually a highly effective treatment for myeloproliferative neoplasms (MPNs) associated with ABL, PDGFRA or PDGFRB gene fusions; however, occasional imatinib-responsive patients have been reported without abnormalities of these genes. To identify novel imatinib-sensitive lesions, we screened 11 BCR-ABL-neg...

journal_title：Leukemia

authors： Chase A,Schultheis B,Kreil S,Baxter J,Hidalgo-Curtis C,Jones A,Zhang L,Grand FH,Melo JV,Cross NC

更新日期：2009-02-01 00:00:00

abstract：:There is abundant evidence that leukemia arise through somatically acquired genetic changes. Familial or congenital predisposition is rarely involved. These genetic changes are often visible as chromosomal aberrations. Molecular analyses of the DNA sequences rearranged in leukemia has demonstrated the presence of cell...

journal_title：Leukemia

authors： Hagemeijer A

更新日期：1992-11-01 00:00:00

abstract：:Bovine leukemia virus-infected sheep were demonstrated to possess a plasma factor that specifically suppresses in vitro virus expression in lymphocyte cultures. This blocking activity is observed even after phytohemagglutinin (PHA) stimulation and is independent of cellular proliferation. Such a factor may play a crit...

journal_title：Leukemia

authors： Cornil I,Levy D

更新日期：1989-02-01 00:00:00

abstract：:An antisense oligodeoxynucleotide (ODN) complementary to the first six codons of the Bcl-2 mRNA, G3139 (oblimersen sodium; Genasense), has been shown to downregulate Bcl-2 and produce responses in a variety of malignancies including drug-resistant lymphoma. Incubation of ex vivo purified plasma cells from patients wit...

journal_title：Leukemia

authors： van de Donk NW,Kamphuis MM,van Dijk M,Borst HP,Bloem AC,Lokhorst HM

更新日期：2003-01-01 00:00:00

abstract：:A series of 60 acute nonlymphocytic leukemias (ANLL) was analyzed for the expression of terminal deoxynucleotidyl transferase (TdT). The detected TdT+ cells were studied in detail by use of double marker analyses for TdT and differentiation markers, such as myeloid markers (CD13 and CD33), B cell markers, T cell marke...

journal_title：Leukemia

authors： Adriaansen HJ,van Dongen JJ,Kappers-Klunne MC,Hählen K,van 't Veer MB,Wijdenes-de Bresser JH,Holdrinet AC,Harthoorn-Lasthuizen EJ,Abels J,Hooijkaas H

更新日期：1990-06-01 00:00:00

abstract：:Myeloid growth factors, such as granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor, have been used to decrease the duration of chemotherapy-induced neutropenia and thereby reduce the incidence and severity of infections in various regimens used to treat acute myeloid leukemia an...

journal_title：Leukemia

authors： Ravandi F

更新日期：2006-04-01 00:00:00